Want to see RPID full AI Analyst Report?
RPID Stock Chart & Stats
$1.66
$0.00(0.00%)
At close: 4:00 PM EDT
$1.66
$0.00(0.00%)
Day’s Range― - ―
52-Week Range$1.09 - $4.94
Previous CloseN/A
Volume24.17K
Average Volume (3M)261.95K
Market Cap
$55.68M
Enterprise Value$87.22
Total Cash (Recent Filing)$19.77M
Total Debt (Recent Filing)$23.48M
Price to Earnings (P/E)―
Beta1.23
Next Earnings
Nov 05, 2026EPS Estimate
-0.2Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.11
Shares Outstanding45,660,027
10 Day Avg. Volume372,780
30 Day Avg. Volume261,947
Financial Highlights & Ratios
PEG Ratio0.99
Price to Book (P/B)3.90
Price to Sales (P/S)3.86
P/FCF Ratio-4.06
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$7.50Price Target Upside351.81% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-0.93
Revenue Forecast (FY)$39.33M
Bulls Say, Bears Say
Bulls Say
Recurring Revenue And Installed-base GrowthRecurring revenue growth and 169 fully validated systems show the installed base is converting into ongoing consumables and service demand. This model can compound beyond individual instrument sales as utilization rises, improving revenue visibility and making commercial progress more durable over the next several quarters.
Improving Gross And Service MarginsGross margin improved to a record 15% from 4% year over year, while service margin reached 49%. The improvement indicates operating execution and mix benefits are emerging; if sustained, higher service profitability can support broader margin expansion as the installed base grows.
Strong Consumables AdoptionConsumables growth above 20% and nine Q2 validations versus two a year earlier indicate stronger adoption and workflow conversion. More validated systems and routine testing should expand recurring consumable pull-through, supporting the company’s stated growth ambitions beyond one-time placements.
Bears Say
Persistent Operating LossesQ2 net loss of $12.9 million and adjusted EBITDA loss of $10.3 million show that improved revenue and gross margin have not yet translated into operating profitability. Continued large losses limit internally funded growth and leave the business dependent on execution and external capital over the medium term.
Negative Cash Generation And Funding DependenceOperating and free cash flow have remained negative across all periods, with Q2 cash usage described as higher than normal. A roughly $20 million cash balance and reliance on debt milestones or warrant proceeds make funding continuity sensitive to operating performance and financing execution.
Negative Product Margin And High Operating ExpenseQ2 product margin remained negative 3% despite improvement, while full-year operating expense guidance is $51–$53 million. The core system economics therefore remain below breakeven and substantial spending continues, delaying scalable profitability until pricing, mix, or cost efficiency improves.
Rapid Micro Biosystems News
RPID FAQ
What was Rapid Micro Biosystems’s price range in the past 12 months?
Rapid Micro Biosystems lowest stock price was $1.09 and its highest was $4.94 in the past 12 months.
What is Rapid Micro Biosystems’s market cap?
Rapid Micro Biosystems’s market cap is $55.68M.
When is Rapid Micro Biosystems’s upcoming earnings report date?
Rapid Micro Biosystems’s upcoming earnings report date is Nov 05, 2026 which is in 40 days.
How were Rapid Micro Biosystems’s earnings last quarter?
Rapid Micro Biosystems released its earnings results on Aug 07, 2026. The company reported -$0.27 earnings per share for the quarter, missing the consensus estimate of -$0.243 by -$0.027.
Is Rapid Micro Biosystems overvalued?
According to Wall Street analysts Rapid Micro Biosystems’s price is currently Undervalued.
Does Rapid Micro Biosystems pay dividends?
Rapid Micro Biosystems does not currently pay dividends.
What is Rapid Micro Biosystems’s EPS estimate?
Rapid Micro Biosystems’s EPS estimate is -0.2.
How many shares outstanding does Rapid Micro Biosystems have?
Rapid Micro Biosystems has 45,660,027 shares outstanding.
What happened to Rapid Micro Biosystems’s price movement after its last earnings report?
Rapid Micro Biosystems reported an EPS of -$0.27 in its last earnings report, missing expectations of -$0.243. Following the earnings report the stock price went down -16.827%.
Which hedge fund is a major shareholder of Rapid Micro Biosystems?
Currently, no hedge funds are holding shares in RPID
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Rapid Micro Biosystems Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$7.50 (351.81% Upside)
$7.50 (351.81% Upside)
Hedge Fund Trend
Decreased
By 192.6K Shares
Last Quarter.
Last Quarter.
Technicals
SMA
Negative
20 days / 200 days
Momentum
-65.42%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-22.67%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Rapid Micro Biosystems
Rapid Micro Biosystems, Inc. operates as a life sciences technology firm, supplying advanced solutions for identifying microbial impurities in the production processes of pharmaceuticals, medical devices, and personal care goods across North America, Europe, and Asia. Central to their offerings is the Growth Direct platform, a comprehensive system comprising the Growth Direct instrument, specialized disposable components, software for seamless integration with laboratory information management systems (LIMS), and extensive customer validation and support services. This innovative platform is designed to automate and modernize traditional, labor-intensive microbial quality control (MQC) testing workflows, which are critical for diverse therapeutic modalities such as biologics, vaccines, cutting-edge cell and gene therapies, and sterile injectable medications. Beyond their core product, the company also delivers essential services, including system installation, verification, expert technical training, and continuous support. Their technologies are widely applied in vital areas like environmental monitoring, water quality testing, bioburden assessment, and final sterility release evaluations. Established in 2006, the company initially traded as Genomic Profiling Systems, Inc., before rebranding to Rapid Micro Biosystems, Inc. in January 2007, and maintains its headquarters in Lowell, Massachusetts.
RPID Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed clear operational momentum: double-digit revenue growth (11% YoY), record consumable performance (>20% growth), a company milestone (200th system), a sizable increase in service margins (to 49%), and a pathway to improving gross margins through H2 2026 and longer-term targets (50% by end of 2028). At the same time, the company remains unprofitable with a Q2 net loss of $12.9M and adjusted EBITDA loss of $10.3M, product margins are still slightly negative, and liquidity depends on achieving debt milestone funding and potential warrant exercises. Overall, management emphasized improving fundamentals and execution while acknowledging remaining execution and financing risks.View all RPID earnings summariesRPID Stock 12 Month Forecast
Average Price Target
$7.50
▲(351.81% Upside)
Technical Analysis
Ownership Overview
32.78% Insiders
3.07% Mutual Funds
32.92% Other Institutional Investors
28.71% Public Companies and
Individual Investors